SK9342003A3 - 3-Indoline derivatives useful in the treatment of psychiatric and neurologic disorders - Google Patents

3-Indoline derivatives useful in the treatment of psychiatric and neurologic disorders Download PDF

Info

Publication number: SK9342003A3
Authority: SK; Slovakia
Prior art keywords: alkyl; acetyl; hydrogen; dihydro; cycloalkyl
Prior art date: 2000-12-22

Application number

SK934-2003A

Other languages

English (en)

Slovak (sk)

Inventor

Jan Kehler

Benny Bang-Andersen

Original Assignee

Lundbeck & Co As H

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-22

Filing date

2001-12-18

Publication date

2003-10-07

2001-12-18 Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H

2003-10-07 Publication of SK9342003A3 publication Critical patent/SK9342003A3/sk

Links

238000011282 treatment Methods 0.000 title claims abstract description 23
208000020016 psychiatric disease Diseases 0.000 title abstract description 4
208000012902 Nervous system disease Diseases 0.000 title abstract description 3
150000001875 compounds Chemical class 0.000 claims abstract description 72
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 43
239000001257 hydrogen Substances 0.000 claims abstract description 42
150000002431 hydrogen Chemical class 0.000 claims abstract description 19
150000003839 salts Chemical class 0.000 claims abstract description 13
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims abstract description 12
229910052736 halogen Inorganic materials 0.000 claims abstract description 12
150000002367 halogens Chemical group 0.000 claims abstract description 12
208000028017 Psychotic disease Diseases 0.000 claims abstract description 11
125000002252 acyl group Chemical group 0.000 claims abstract description 11
125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 claims abstract description 11
239000002253 acid Substances 0.000 claims abstract description 10
239000003814 drug Substances 0.000 claims abstract description 10
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 10
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 10
125000003118 aryl group Chemical group 0.000 claims abstract description 9
125000000882 C2-C6 alkenyl group Chemical group 0.000 claims abstract description 8
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 8
125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 7
125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims abstract description 6
125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims abstract description 6
125000003601 C2-C6 alkynyl group Chemical group 0.000 claims abstract description 6
125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims abstract description 5
238000004519 manufacturing process Methods 0.000 claims abstract description 5
125000003441 thioacyl group Chemical group 0.000 claims abstract description 5
125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims abstract description 4
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical group C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 claims abstract description 4
125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 4
125000003386 piperidinyl group Chemical group 0.000 claims abstract description 4
125000000719 pyrrolidinyl group Chemical group 0.000 claims abstract description 4
125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 5
125000006619 (C1-C6) dialkylamino group Chemical group 0.000 claims abstract 3
125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims abstract 2
125000000217 alkyl group Chemical group 0.000 claims description 45
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
230000000694 effects Effects 0.000 claims description 19
-1 C 2 _6alkinyl Chemical group 0.000 claims description 16
208000019901 Anxiety disease Diseases 0.000 claims description 15
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 14
208000019695 Migraine disease Diseases 0.000 claims description 11
208000024891 symptom Diseases 0.000 claims description 11
206010027599 migraine Diseases 0.000 claims description 10
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 9
125000003342 alkenyl group Chemical group 0.000 claims description 9
125000000753 cycloalkyl group Chemical group 0.000 claims description 9
201000000980 schizophrenia Diseases 0.000 claims description 9
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 8
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 8
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 8
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 7
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 7
230000016571 aggressive behavior Effects 0.000 claims description 7
125000000304 alkynyl group Chemical group 0.000 claims description 7
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 6
239000000164 antipsychotic agent Substances 0.000 claims description 6
230000006872 improvement Effects 0.000 claims description 6
208000019906 panic disease Diseases 0.000 claims description 6
230000007958 sleep Effects 0.000 claims description 6
208000012661 Dyskinesia Diseases 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 5
125000001309 chloro group Chemical group Cl* 0.000 claims description 5
239000003085 diluting agent Substances 0.000 claims description 5
125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 4
208000010877 cognitive disease Diseases 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 3
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 3
125000004414 alkyl thio group Chemical group 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
229910052731 fluorine Inorganic materials 0.000 claims description 3
239000011737 fluorine Substances 0.000 claims description 3
125000005843 halogen group Chemical group 0.000 claims description 3
229910052757 nitrogen Inorganic materials 0.000 claims description 3
125000003282 alkyl amino group Chemical group 0.000 claims description 2
125000001153 fluoro group Chemical group F* 0.000 claims description 2
MRJNWXMBQHMRSW-UHFFFAOYSA-N 1-[3-[2-[4-(3,4-dichlorophenyl)-3,6-dihydro-2h-pyridin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)CC1CCN(CC=1)CCC=1C1=CC=C(Cl)C(Cl)=C1 MRJNWXMBQHMRSW-UHFFFAOYSA-N 0.000 claims 2
VIHFYGJNDLKWET-UHFFFAOYSA-N 1-[3-[2-[4-(3,4-dichlorophenyl)piperidin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)CC1CCN(CC1)CCC1C1=CC=C(Cl)C(Cl)=C1 VIHFYGJNDLKWET-UHFFFAOYSA-N 0.000 claims 2
UBCONEKRLSAWBT-UHFFFAOYSA-N 1-[3-[2-[4-(3,4-dimethylphenyl)piperazin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)CC1CCN(CC1)CCN1C1=CC=C(C)C(C)=C1 UBCONEKRLSAWBT-UHFFFAOYSA-N 0.000 claims 2
JMCBHCLPCVFMFE-UHFFFAOYSA-N 1-[3-[2-[4-(4-bromophenyl)piperazin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)CC1CCN(CC1)CCN1C1=CC=C(Br)C=C1 JMCBHCLPCVFMFE-UHFFFAOYSA-N 0.000 claims 2
JEKSUNRNVHPMLN-UHFFFAOYSA-N 1-[3-[2-[4-(4-methylphenyl)piperazin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)CC1CCN(CC1)CCN1C1=CC=C(C)C=C1 JEKSUNRNVHPMLN-UHFFFAOYSA-N 0.000 claims 1
230000001149 cognitive effect Effects 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 1
SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 1
125000006621 (C3-C8) cycloalkyl-(C1-C6) alkyl group Chemical group 0.000 abstract description 4
229910052799 carbon Inorganic materials 0.000 abstract description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 32
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
102000005962 receptors Human genes 0.000 description 23
108020003175 receptors Proteins 0.000 description 23
229960003638 dopamine Drugs 0.000 description 16
239000000203 mixture Substances 0.000 description 16
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
238000000034 method Methods 0.000 description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 8
150000001412 amines Chemical class 0.000 description 7
239000005557 antagonist Substances 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003446 ligand Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
102000049773 5-HT2A Serotonin Receptor Human genes 0.000 description 4
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
108090000357 Dopamine D4 receptors Proteins 0.000 description 4
102000003962 Dopamine D4 receptors Human genes 0.000 description 4
SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
230000029936 alkylation Effects 0.000 description 4
238000005804 alkylation reaction Methods 0.000 description 4
230000000561 anti-psychotic effect Effects 0.000 description 4
150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
239000000018 receptor agonist Substances 0.000 description 4
229940044601 receptor agonist Drugs 0.000 description 4
239000002464 receptor antagonist Substances 0.000 description 4
229940044551 receptor antagonist Drugs 0.000 description 4
230000009467 reduction Effects 0.000 description 4
238000006722 reduction reaction Methods 0.000 description 4
239000000741 silica gel Substances 0.000 description 4
229910002027 silica gel Inorganic materials 0.000 description 4
239000002904 solvent Substances 0.000 description 4
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
239000000654 additive Substances 0.000 description 3
239000002671 adjuvant Substances 0.000 description 3
238000003556 assay Methods 0.000 description 3
238000009835 boiling Methods 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
150000001735 carboxylic acids Chemical class 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
239000003480 eluent Substances 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
239000000284 extract Substances 0.000 description 3
238000003818 flash chromatography Methods 0.000 description 3
239000012458 free base Substances 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
229940125723 sedative agent Drugs 0.000 description 3
239000000932 sedative agent Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
FPCCSQOGAWCVBH-PSQIVULCSA-N 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]-1,1,2,2-tetratritioethyl]-1h-quinazoline-2,4-dione Chemical compound O=C1NC2=CC=CC=C2C(=O)N1C([3H])([3H])C([3H])([3H])N(CC1)CCC1C(=O)C1=CC=C(F)C=C1 FPCCSQOGAWCVBH-PSQIVULCSA-N 0.000 description 2
IREIFEVUVSLMAZ-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)piperidine Chemical compound C1=C(Cl)C(Cl)=CC=C1C1CCNCC1 IREIFEVUVSLMAZ-UHFFFAOYSA-N 0.000 description 2
108010072564 5-HT2A Serotonin Receptor Proteins 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
101150104779 HTR2A gene Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
230000010933 acylation Effects 0.000 description 2
238000005917 acylation reaction Methods 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
230000008485 antagonism Effects 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
230000036506 anxiety Effects 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
229960004170 clozapine Drugs 0.000 description 2
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 2
230000002301 combined effect Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
239000007822 coupling agent Substances 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
238000010828 elution Methods 0.000 description 2
XXSSQRNKZXFMJP-UHFFFAOYSA-N ethyl 4-(3,4-dichlorophenyl)-4-hydroxypiperidine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCC1(O)C1=CC=C(Cl)C(Cl)=C1 XXSSQRNKZXFMJP-UHFFFAOYSA-N 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
125000004356 hydroxy functional group Chemical group O* 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
239000012948 isocyanate Chemical class 0.000 description 2
150000002513 isocyanates Chemical class 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000002245 particle Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
238000005932 reductive alkylation reaction Methods 0.000 description 2
238000010992 reflux Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
230000000698 schizophrenic effect Effects 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
DKGZKTPJOSAWFA-UHFFFAOYSA-N spiperone Chemical compound C1=CC(F)=CC=C1C(=O)CCCN1CCC2(C(NCN2C=2C=CC=CC=2)=O)CC1 DKGZKTPJOSAWFA-UHFFFAOYSA-N 0.000 description 2
108010092215 spiroperidol receptor Proteins 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
229910052717 sulfur Inorganic materials 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 2
AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
150000003672 ureas Chemical class 0.000 description 2
125000006636 (C3-C8) cycloalkylcarbonyl group Chemical group 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
PXFJLKKZSWWVRX-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)piperazine Chemical compound C1=C(Cl)C(Cl)=CC=C1N1CCNCC1 PXFJLKKZSWWVRX-UHFFFAOYSA-N 0.000 description 1
SFLNVAVCCYTHCQ-UHFFFAOYSA-N 1-(3,4-dimethylphenyl)piperazine Chemical compound C1=C(C)C(C)=CC=C1N1CCNCC1 SFLNVAVCCYTHCQ-UHFFFAOYSA-N 0.000 description 1
YDVSFRZKQMQPJD-UHFFFAOYSA-N 1-(4-bromophenyl)piperazine;hydrochloride Chemical compound [Cl-].C1=CC(Br)=CC=C1N1CC[NH2+]CC1 YDVSFRZKQMQPJD-UHFFFAOYSA-N 0.000 description 1
ONEYFZXGNFNRJH-UHFFFAOYSA-N 1-(4-methylphenyl)piperazine Chemical compound C1=CC(C)=CC=C1N1CCNCC1 ONEYFZXGNFNRJH-UHFFFAOYSA-N 0.000 description 1
BMMNRSGMLQWXHY-UHFFFAOYSA-N 1-[3-[2-[4-(4-bromophenyl)piperazin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone hydrochloride Chemical compound Cl.C12=CC=CC=C2N(C(=O)C)CC1CCN(CC1)CCN1C1=CC=C(Br)C=C1 BMMNRSGMLQWXHY-UHFFFAOYSA-N 0.000 description 1
CWEVFFGJOWGALY-UHFFFAOYSA-N 1-[3-[2-[4-(4-methylphenyl)piperidin-1-yl]ethyl]-2,3-dihydroindol-1-yl]ethanone Chemical compound C12=CC=CC=C2N(C(=O)C)CC1CCN(CC1)CCC1C1=CC=C(C)C=C1 CWEVFFGJOWGALY-UHFFFAOYSA-N 0.000 description 1
HCYFGRCYSCXKNQ-UHFFFAOYSA-N 2-(1,3-dimethyl-2,6-dioxo-7-purinyl)acetic acid Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)=O)C=N2 HCYFGRCYSCXKNQ-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical class CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
REEHSAJWGAOIIW-UHFFFAOYSA-N 3,6-dihydro-2h-pyridine Chemical compound C1CC=CC[N]1 REEHSAJWGAOIIW-UHFFFAOYSA-N 0.000 description 1
QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
OENHQMQUZYKXFG-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-1,2,3,6-tetrahydropyridine Chemical compound C1=C(Cl)C(Cl)=CC=C1C1=CCNCC1 OENHQMQUZYKXFG-UHFFFAOYSA-N 0.000 description 1
UWILYNPREMNRTF-UHFFFAOYSA-N 4-(4-methylphenyl)piperidine Chemical compound C1=CC(C)=CC=C1C1CCNCC1 UWILYNPREMNRTF-UHFFFAOYSA-N 0.000 description 1
CFPZDVAZISWERM-UHFFFAOYSA-N 4-bromo-1,2-dichlorobenzene Chemical compound ClC1=CC=C(Br)C=C1Cl CFPZDVAZISWERM-UHFFFAOYSA-N 0.000 description 1
125000000242 4-chlorobenzoyl group Chemical group ClC1=CC=C(C(=O)*)C=C1 0.000 description 1
102000035038 5-HT1 receptors Human genes 0.000 description 1
108091005478 5-HT1 receptors Proteins 0.000 description 1
102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
206010001488 Aggression Diseases 0.000 description 1
208000007848 Alcoholism Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
208000009132 Catalepsy Diseases 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
244000223760 Cinnamomum zeylanicum Species 0.000 description 1
WYZICOWLRBEPLA-UHFFFAOYSA-N Cl.C(C)(=O)N1CC(C2=CC=CC=C12)CCN1CCN(CC1)C1=CC(=C(C=C1)C)C Chemical compound Cl.C(C)(=O)N1CC(C2=CC=CC=C12)CCN1CCN(CC1)C1=CC(=C(C=C1)C)C WYZICOWLRBEPLA-UHFFFAOYSA-N 0.000 description 1
VGZIGUMTYCFQAE-UHFFFAOYSA-N Cl.C(C)(=O)N1CC(C2=CC=CC=C12)CCN1CCN(CC1)C1=CC(=C(C=C1)Cl)Cl Chemical compound Cl.C(C)(=O)N1CC(C2=CC=CC=C12)CCN1CCN(CC1)C1=CC(=C(C=C1)Cl)Cl VGZIGUMTYCFQAE-UHFFFAOYSA-N 0.000 description 1
DXCCTQNGYPBBNU-UHFFFAOYSA-N Cl.C(C)(=O)N1CC(C2=CC=CC=C12)CCN1CCN(CC1)C1=CC=C(C=C1)C Chemical compound Cl.C(C)(=O)N1CC(C2=CC=CC=C12)CCN1CCN(CC1)C1=CC=C(C=C1)C DXCCTQNGYPBBNU-UHFFFAOYSA-N 0.000 description 1
208000028698 Cognitive impairment Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000017911 HTR1A Human genes 0.000 description 1
101150015707 HTR1A gene Proteins 0.000 description 1
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 1
238000003109 Karl Fischer titration Methods 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical class O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
206010047853 Waxy flexibility Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
229950003769 acefylline Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
208000012761 aggressive behavior Diseases 0.000 description 1
229910000086 alane Inorganic materials 0.000 description 1
201000007930 alcohol dependence Diseases 0.000 description 1
230000002152 alkylating effect Effects 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
230000002539 anti-aggressive effect Effects 0.000 description 1
230000001430 anti-depressive effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
125000005129 aryl carbonyl group Chemical group 0.000 description 1
229940127236 atypical antipsychotics Drugs 0.000 description 1
239000002585 base Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000002619 bicyclic group Chemical group 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000001246 bromo group Chemical group Br* 0.000 description 1
125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
235000013339 cereals Nutrition 0.000 description 1
150000001793 charged compounds Chemical class 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
230000007278 cognition impairment Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
229940125846 compound 25 Drugs 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229960003368 croscarmellose sodium type a Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000000706 effect on dopamine Effects 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
LUBGFMZTGFXIIN-UHFFFAOYSA-N ethyl 4-oxopiperidine-1-carboxylate Chemical compound CCOC(=O)N1CCC(=O)CC1 LUBGFMZTGFXIIN-UHFFFAOYSA-N 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000005095 gastrointestinal system Anatomy 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000001863 hydroxypropyl cellulose Substances 0.000 description 1
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
150000002476 indolines Chemical class 0.000 description 1
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000010354 integration Effects 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000002576 ketones Chemical class 0.000 description 1
238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
239000012280 lithium aluminium hydride Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
238000002156 mixing Methods 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
239000002547 new drug Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000012074 organic phase Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N palmitic acid group Chemical group C(CCCCCCCCCCCCCCC)(=O)O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
239000004031 partial agonist Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000003884 phenylalkyl group Chemical group 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
150000003053 piperidines Chemical class 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
229960003415 propylparaben Drugs 0.000 description 1
125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
210000005227 renal system Anatomy 0.000 description 1
238000012552 review Methods 0.000 description 1
239000012047 saturated solution Substances 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000003478 serotonin 5-HT2 receptor agonist Substances 0.000 description 1
239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 description 1
108010085082 sigma receptors Proteins 0.000 description 1
230000003860 sleep quality Effects 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
229950004288 tosilate Drugs 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229910052727 yttrium Inorganic materials 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SK934-2003A 2000-12-22 2001-12-18 3-Indoline derivatives useful in the treatment of psychiatric and neurologic disorders SK9342003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DKPA200001931		2000-12-22
PCT/DK2001/000835 WO2002051833A1 (en)	2000-12-22	2001-12-18	3-indoline derivatives useful in the treatment of psychiatric and neurologic disorders

Publications (1)

Publication Number	Publication Date
SK9342003A3 true SK9342003A3 (en)	2003-10-07

Family

ID=8159925

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK934-2003A SK9342003A3 (en)	2000-12-22	2001-12-18	3-Indoline derivatives useful in the treatment of psychiatric and neurologic disorders

Country Status (20)

Country	Link
US (1)	US20040044007A1 (cs)
EP (1)	EP1345921A1 (cs)
JP (1)	JP2004516321A (cs)
KR (1)	KR20030063455A (cs)
CN (1)	CN1491223A (cs)
AR (1)	AR035521A1 (cs)
BG (1)	BG107982A (cs)
BR (1)	BR0116365A (cs)
CA (1)	CA2432473A1 (cs)
CZ (1)	CZ20032004A3 (cs)
EA (1)	EA200300718A1 (cs)
HU (1)	HUP0500350A2 (cs)
IL (1)	IL156340A0 (cs)
IS (1)	IS6837A (cs)
MX (1)	MXPA03005555A (cs)
NO (1)	NO20032636D0 (cs)
PL (1)	PL362133A1 (cs)
SK (1)	SK9342003A3 (cs)
WO (1)	WO2002051833A1 (cs)
ZA (1)	ZA200304643B (cs)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ITMI20012060A1 (it) *	2001-10-05	2003-04-05	Recordati Chem Pharm	Nuovi eterocilcli n-acilati
US8754238B2 (en)	2003-07-22	2014-06-17	Arena Pharmaceuticals, Inc.	Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
US7884096B2 (en)	2003-12-02	2011-02-08	Pharmaneuroboost N.V.	Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP2272514A1 (en)	2003-12-02	2011-01-12	PharmaNeuroBoost N.V.	Use of low dose pipamperone and a second active compound in the treatment of neurodegenerative diseases
US7855195B2 (en)	2003-12-02	2010-12-21	Pharmaneuroboost N.V.	Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
EP1727803B3 (en)	2004-03-23	2014-04-23	Arena Pharmaceuticals, Inc.	Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl)phenyl] ureas and intermediates thereof
HRP20080129T3 (en) *	2004-05-11	2008-04-30	EGIS Gy�gyszergy�r Nyrt	Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders
HRP20060402A2 (hr) *	2004-05-11	2007-06-30	Egis Gy�gyszergy�r Nyrt.	Derivati piridina alkilnih oksindola kao 5-ht7 receptorski aktivni agensi
AR052308A1 (es) *	2004-07-16	2007-03-14	Lundbeck & Co As H	Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
PE20061130A1 (es)	2004-11-19	2007-01-05	Arena Pharm Inc	Derivados de 3-fenil-pirazol como moduladores del receptor de serotonina 5-ht2a
US8148418B2 (en)	2006-05-18	2012-04-03	Arena Pharmaceuticals, Inc.	Ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
USRE45336E1 (en)	2006-05-18	2015-01-13	Arena Pharmaceuticals, Inc.	Primary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
NZ594353A (en)	2006-05-18	2013-02-22	Arena Pharm Inc	Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
TWI415845B (zh)	2006-10-03	2013-11-21	Arena Pharm Inc	用於治療與５-ｈｔ2ａ血清素受體相關聯病症之作為５-ｈｔ2ａ血清素受體之調節劑的吡唑衍生物
KR100868353B1 (ko) *	2007-03-08	2008-11-12	한국화학연구원	도파민 ｄ4 수용체 길항제인 신규 피페라지닐프로필피라졸유도체, 이의 제조방법 및 이를 포함하는 약학적 조성물
JP5393677B2 (ja)	2007-08-15	2014-01-22	アリーナファーマシューティカルズ，インコーポレイテッド	５−ＨＴ２Ａセロトニン受容体に関連した障害の治療のための５−ＨＴ２Ａセロトニン受容体のモジュレーターとしてのイミダゾ［１，２−ａ］ピリジン誘導体
US20110021538A1 (en)	2008-04-02	2011-01-27	Arena Pharmaceuticals, Inc.	Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
KR101062376B1 (ko)	2008-04-10	2011-09-06	한국화학연구원	신규 인돌 카르복실산 비스피리딜 카르복사마이드 유도체,이의 제조방법 및 이를 유효성분으로 함유하는 조성물
HRP20180589T1 (hr)	2008-10-28	2018-05-18	Arena Pharmaceuticals, Inc.	Pripravci modulatora serotoninskog receptora 5-ht2a koji su korisni za liječenje s njim povezanih poremećaja
WO2010062321A1 (en)	2008-10-28	2010-06-03	Arena Pharmaceuticals, Inc.	Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US8980891B2 (en)	2009-12-18	2015-03-17	Arena Pharmaceuticals, Inc.	Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
CN106243088B (zh)	2015-06-03	2019-01-04	广东东阳光药业有限公司	取代的哌嗪化合物及其使用方法和用途
RU2017145976A (ru)	2015-06-12	2019-07-15	Аксовант Сайенсиз Гмбх	Производные диарил- и арилгетероарилмочевины, применимые для профилактики и лечения нарушения поведения во время REM-фазы сна
TW201720439A (zh)	2015-07-15	2017-06-16	Axovant Sciences Gmbh	用於預防及治療與神經退化性疾病相關的幻覺之作為５－ｈｔ２ａ血清素受體的二芳基及芳基雜芳基脲衍生物
WO2021139874A1 (en) *	2020-01-06	2021-07-15	Anima	Cognitive disorder prevention and therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3751417A (en) *	1971-08-12	1973-08-07	American Cyanamid Co	1-acyl-3-(2-(4-phenyl-1-piperazinyl)ethyl)indolines
US3900563A (en) *	1973-06-18	1975-08-19	American Cyanamid Co	Method of using 3-(2-(4-phenyl-1-piperazinyl)ethyl)-indolines
US4302589A (en) *	1980-05-08	1981-11-24	American Cyanamid Company	Cis-mono and disubstituted-2-methyl-3-[(piperazinyl) and (piperidino)ethyl]indolines, intermediates for their preparation and methods of preparation
GB8830312D0 (en) *	1988-12-28	1989-02-22	Lundbeck & Co As H	Heterocyclic compounds
DE4101686A1 (de) *	1991-01-22	1992-07-23	Merck Patent Gmbh	Indolderivate
NZ243065A (en) *	1991-06-13	1995-07-26	Lundbeck & Co As H	Piperidine derivatives and pharmaceutical compositions
GB9305623D0 (en) *	1993-03-18	1993-05-05	Merck Sharp & Dohme	Therapeutic agents
DE19512639A1 (de) *	1995-04-05	1996-10-10	Merck Patent Gmbh	Benzonitrile und -fluoride
ITMI20012060A1 (it) *	2001-10-05	2003-04-05	Recordati Chem Pharm	Nuovi eterocilcli n-acilati

2001
- 2001-12-17 AR ARP010105843A patent/AR035521A1/es not_active Application Discontinuation
- 2001-12-18 WO PCT/DK2001/000835 patent/WO2002051833A1/en not_active Ceased
- 2001-12-18 CA CA002432473A patent/CA2432473A1/en not_active Abandoned
- 2001-12-18 CN CNA018227481A patent/CN1491223A/zh active Pending
- 2001-12-18 JP JP2002552928A patent/JP2004516321A/ja not_active Withdrawn
- 2001-12-18 EA EA200300718A patent/EA200300718A1/ru unknown
- 2001-12-18 BR BR0116365-5A patent/BR0116365A/pt not_active Application Discontinuation
- 2001-12-18 CZ CZ20032004A patent/CZ20032004A3/cs unknown
- 2001-12-18 MX MXPA03005555A patent/MXPA03005555A/es unknown
- 2001-12-18 ZA ZA200304643A patent/ZA200304643B/en unknown
- 2001-12-18 EP EP01271969A patent/EP1345921A1/en not_active Withdrawn
- 2001-12-18 SK SK934-2003A patent/SK9342003A3/sk unknown
- 2001-12-18 PL PL36213301A patent/PL362133A1/xx unknown
- 2001-12-18 KR KR10-2003-7008437A patent/KR20030063455A/ko not_active Withdrawn
- 2001-12-18 HU HU0500350A patent/HUP0500350A2/hu unknown
- 2001-12-18 IL IL15634001A patent/IL156340A0/xx unknown
2003
- 2003-06-05 IS IS6837A patent/IS6837A/is unknown
- 2003-06-11 NO NO20032636A patent/NO20032636D0/no not_active Application Discontinuation
- 2003-06-17 US US10/601,347 patent/US20040044007A1/en not_active Abandoned
- 2003-07-08 BG BG107982A patent/BG107982A/bg unknown

Also Published As

Publication number	Publication date
BR0116365A (pt)	2004-07-06
CA2432473A1 (en)	2002-07-04
NO20032636L (no)	2003-06-11
EA200300718A1 (ru)	2003-10-30
US20040044007A1 (en)	2004-03-04
MXPA03005555A (es)	2004-03-26
CZ20032004A3 (cs)	2003-10-15
WO2002051833A1 (en)	2002-07-04
KR20030063455A (ko)	2003-07-28
IL156340A0 (en)	2004-01-04
ZA200304643B (en)	2004-07-19
PL362133A1 (en)	2004-10-18
NO20032636D0 (no)	2003-06-11
IS6837A (is)	2003-06-05
HUP0500350A2 (hu)	2005-08-29
CN1491223A (zh)	2004-04-21
AR035521A1 (es)	2004-06-02
JP2004516321A (ja)	2004-06-03
BG107982A (bg)	2004-08-31
EP1345921A1 (en)	2003-09-24

Publication	Publication Date	Title
SK9342003A3 (en)	2003-10-07	3-Indoline derivatives useful in the treatment of psychiatric and neurologic disorders
SK81399A3 (en)	1999-12-10	Substituted indane and dihydroindole compounds, pharmaceutical composition them containing and their use
SK11062002A3 (sk)	2002-12-03	Fenylpiperazínové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
SK9442002A3 (en)	2002-11-06	Substituted phenyl-piperazine derivatives, their preparation and use
US7223765B2 (en)	2007-05-29	4-phenyl-1-piperazinyl, -piperidinyl and -tetrahydropyridyl derivatives
EP1309586B1 (en)	2006-03-22	4-, 5-, 6- and 7-indole derivatives useful for the treatment of cns disorders
HU201543B (en)	1990-11-28	Process for production of derivatives of 2-(/piperin-4-il/-methil/)-1,2,3,4-tetrahydro-izoquinoline and medical compositions containing them
SK9452002A3 (en)	2002-11-06	Indole derivatives, pharmaceutical composition containing the same and their use
DE60130691T2 (de)	2008-07-17	Indolderivate zur Behandlung von Erkrankungen des Zentralnervensystems
SK1092003A3 (en)	2003-05-02	Indole derivatives useful for the treatment of CNS disorders
EP1299384B1 (en)	2004-03-24	Indole derivatives useful for the treatment of cns disorders
CN101243075A (zh)	2008-08-13	新颖的2,3-二氢吲哚化合物
AU2002221576A1 (en)	2002-07-08	3-indoline derivatives useful in the treatment of psychiatric and neurologic disorders
SK512003A3 (en)	2003-05-02	Indole derivatives useful for the treatment of CNS disorders
SK402003A3 (en)	2003-07-01	Indole derivatives, pharmaceutical composition comprising same and their use
HK1123550A (en)	2009-06-19	Novel 2,3-dihydroindole compounds
MXPA02012149A (en)	2008-10-03	Indole derivatives useful for the treatment of cns disorders